Crinetics Pharmaceuticals, Inc. (CRNX)
| Market Cap | 4.43B |
| Revenue (ttm) | 1.54M |
| Net Income (ttm) | -423.10M |
| Shares Out | 94.89M |
| EPS (ttm) | -4.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 566,608 |
| Open | 47.52 |
| Previous Close | 47.42 |
| Day's Range | 46.65 - 47.83 |
| 52-Week Range | 24.10 - 60.34 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 71.00 (+52.13%) |
| Earnings Date | Nov 6, 2025 |
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candida... [Read more]
Financial Performance
In 2024, Crinetics Pharmaceuticals's revenue was $1.04 million, a decrease of -74.11% compared to the previous year's $4.01 million. Losses were -$298.41 million, 39.1% more than in 2023.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CRNX stock is "Buy." The 12-month stock price target is $71.0, which is an increase of 52.13% from the latest price.
News
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with...
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year
Boston-based MPM BioImpact sold 428,975 shares of Crinetics Pharmaceuticals worth about $12.3 million in the third quarter. The move marked a full exit for MPM, which reported holding no shares of CRN...
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
CAREFNDR underscores the potential clinical value of p altusotine b eyond acromegaly, and demonstrates progress in Crinetics' commitment to addressing unmet needs in the neuroendocrine tumor community...
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-...
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday
The biotech unveiled its third-quarter results. They didn't meet analyst expectations, but there was good news in the update.
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. ( CRNX) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Gayathri Diwakar - Senior Director of Investor Relations R. Struthers - Founder, Presid...
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends Reiterates Cash Burn of $340-370M and Cash Runway in...
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effect...
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-q...
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after...
Is Crinetics Pharmaceuticals Stock a Buy?
Crinetics Pharmaceuticals (CRNX 27.92%) faces the ultimate biotech paradox: Its newly approved drug Palsonify could either justify the stock's $4.3 billion valuation or expose it as dangerously overpr...
Crinetics: FDA Approval And Expansion Of Palsonify In Focus, Maintaining 'Buy' Rating
Crinetics Pharmaceuticals received FDA approval for PALSONIFY, the first daily oral therapy for adults with Acromegaly, addressing a large unmet need. The company has submitted a Marketing Authorizati...
Crinetics Pharmaceuticals, Inc. - Special Call
Crinetics Pharmaceuticals, Inc. - Special Call Company Participants Gayathri Diwakar - Senior Director of Investor Relations R. Struthers - Founder, President, CEO & Director Dana Pizzuti - Chief Medi...
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 tr...
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted no...
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for a...
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qu...
Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan S. Krasner - Corporate Participant Chief Endocrinologist - Corporate...
Crinetics (CRNX) Q2 Revenue Jumps 150%
Crinetics (CRNX) Q2 Revenue Jumps 150%
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progress on the...
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after ...
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qual...
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patie...
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that it will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, ...